DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

Information source: University of Texas Southwestern Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Metoprolol succinate (Drug); Nebivolol (Drug); Hydrochlorothiazide (Drug); DEFINITY® (Drug); Non-invasive measurement of Cardiac Output (CO) (Procedure); Flow mediated vasodilation (Procedure); Endothelial cell collection (Procedure); Microvascular perfusion assessment using Definity (Procedure)

Phase: Phase 4

Status: Recruiting

Sponsored by: University of Texas Southwestern Medical Center

Official(s) and/or principal investigator(s):
Wanpen Vongpatanasin, MD, Principal Investigator, Affiliation: UT Southwestern Medical Center

Overall contact:
Debbie Arbique, MS, FNP-C, Phone: (214) 648-3188, Email: Debbie.Arbique@UTSouthwestern.edu

Summary

The purpose of this study is to determine if Nebivolol improves microvascular perfusion in skeletal muscle during exercise in hypertensive patients and whether this improvement is accompanied by reduction in vascular oxidative stress or increased endothelial nitric oxide synthase (eNOS) expression in humans.

Clinical Details

Official title: Effects of Nebivolol on Microvascular Perfusion in the Skeletal Muscles During Exercise in Hypertensive Patients

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome:

Endothelial cell protein expression

Endothelial cell protein expression

Microvascular blood flow

Microvascular blood flow

Secondary outcome:

Flow mediated dilation (FMD)

Flow mediated dilation (FMD)

Detailed description: In 32 untreated stage 1 hypertensive subjects, the investigators will measure blood pressure; noninvasive cardiac output by thoracic electrical bioimpedance (Bioz, Cardio Dynamics); forearm mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function; collect venous endothelial cells; and measure microvascular perfusion using an Octafluoropropane microbubble contrast agent (Definity). To obtain FMD, the brachial artery will be imaged using ultrasound. After a clear picture has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter. To collect endothelial cells, a thin wire will be inserted in the vein to collect cells from the inner lining of the vein. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique. To assess the microvascular perfusion in the skeletal muscle, a contrast agent (Definity) will be administered at baseline and after 5 minutes of rhythmic hand grip exercise at 30% of maximal voluntary contraction. The investigators will then randomize our subjects to receive 12 weeks of Metoprolol or Nebivolol, using a cross over design. There will be a 4 week washout period between the two treatments. During the washout period, subjects will be followed after 2 weeks of drug withdrawal. Subjects found to have BP > 140/90 mmHg then, will be started on hydrochlorothiazide (HCTZ) at 25 mg once daily. Then subjects will be asked to return in 2 weeks. At that time HCTZ will be stopped if started in the earlier visit, and subject will be switched to the remaining treatment (Nebivolol or Metoprolol). Then, the investigators will assess microvascular perfusion in the skeletal muscle at rest and during handgrip exercise, endothelial function (FMD), and changes in endothelial cell protein expression after 12 weeks of Nebivolol and after 12 weeks of Metoprolol treatment in the same subjects.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Men and women with stage I primary untreated hypertension (BP between 140-159/90-99

mmHg)

- Age 18-65

Exclusion Criteria:

- Congestive heart failure

- Coronary artery disease

- Left ventricular hypertrophy by echocardiography or ECG

- History of stroke

- Average blood pressure >159/99 mmHg

- Bradycardia with a resting heart rate <55 bpm

- Chronic kidney disease with a serum creatinine > 1. 4 mg/dL

- Asthma or chronic obstructive pulmonary disease

- Women who are pregnant or planning to become pregnant

- Hypersensitivity to beta blockers, hydrochlorothiazide, or Definity

- Any history of substance abuse (other than tobacco)

- Concomitant drug treatment which raises endogenous nitric oxide levels, including

nitrates or phosphodiesterase V inhibitors (Viagra, Levitra)

- History of symptomatic bradycardia or heart block

- Patients with Right-to-left, bidirectional, or transient right-to-left cardiac shunts

- Hypersensitivity to perflutren, blood, blood products or albumin.

Locations and Contacts

Debbie Arbique, MS, FNP-C, Phone: (214) 648-3188, Email: Debbie.Arbique@UTSouthwestern.edu

UT Southwestern Medical Center, Dallas, Texas 75390-8586, United States; Recruiting
Debbie Arbique, MS, FNP-C, Phone: 214-648-3188, Email: Debbie.Arbique@UTSouthwestern.edu
Angela L Price, MD, Phone: (214) 648-3188, Email: Angela.Price@UTSouthwestern.edu
Wanpen Vongpatanasin, MD, Principal Investigator
Additional Information

Related publications:

Hamada M, Kazatani Y, Shigematsu Y, Ito T, Kokubu T, Ishise S. Enhanced blood pressure response to isometric handgrip exercise in patients with essential hypertension: effects of propranolol and prazosin. J Hypertens. 1987 Jun;5(3):305-9.

Saitoh M, Miyakoda H, Kitamura H, Kinugawa T, Hisatome I, Kotake H, Mashiba H. Cardiovascular and sympathetic nervous response to dynamic exercise in patients with essential hypertension. Intern Med. 1992 May;31(5):606-10.

Glezer GA, Lediashova GA. Changes in general haemodynamics and renal function during exercise in patients with arterial hypertension. Cor Vasa. 1975;17(1):1-13.

Kazatani Y, Hamada M, Shigematsu Y, Hiwada K, Kokubu T. Beneficial Effect of a Long-Term Antihypertensive Therapy on Blood Pressure Response to Isometric Handgrip Exercise in Patients with Essential Hypertension. Am J Ther. 1995 Mar;2(3):165-169.

Marraccini P, Palombo C, Giaconi S, Michelassi C, Genovesi-Ebert A, Marabotti C, Fommei E, Ghione S, L'Abbate A. Reduced cardiovascular efficiency and increased reactivity during exercise in borderline and established hypertension. Am J Hypertens. 1989 Dec;2(12 Pt 1):913-6.

Kokkinos PF, Andreas PE, Coutoulakis E, Colleran JA, Narayan P, Dotson CO, Choucair W, Farmer C, Fernhall B. Determinants of exercise blood pressure response in normotensive and hypertensive women: role of cardiorespiratory fitness. J Cardiopulm Rehabil. 2002 May-Jun;22(3):178-83.

Schütz W, Hörtnagl H, Magometschnigg D. Function of the autonomic nervous system in young, untreated hypertensive patients. Int J Cardiol. 1986 Feb;10(2):133-40.

Goodman JM, McLaughlin PR, Plyley MJ, Holloway RM, Fell D, Logan AG, Liu PP. Impaired cardiopulmonary response to exercise in moderate hypertension. Can J Cardiol. 1992 May;8(4):363-71.

Lund-Johansen P. Twenty-year follow-up of hemodynamics in essential hypertension during rest and exercise. Hypertension. 1991 Nov;18(5 Suppl):III54-61.

de Champlain J, Petrovich M, Gonzalez M, Lebeau R, Nadeau R. Abnormal cardiovascular reactivity in borderline and mild essential hypertension. Hypertension. 1991 Apr;17(4 Suppl):III22-8.

Zhao W, Swanson SA, Ye J, Li X, Shelton JM, Zhang W, Thomas GD. Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension. Hypertension. 2006 Oct;48(4):637-43. Epub 2006 Aug 28.

Ladage D, Brixius K, Hoyer H, Steingen C, Wesseling A, Malan D, Bloch W, Schwinger RH. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol. 2006 Aug;33(8):720-4.

Reidenbach C, Schwinger RH, Steinritz D, Kehe K, Thiermann H, Klotz T, Sommer F, Bloch W, Brixius K. Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum. Life Sci. 2007 Jun 6;80(26):2421-7. Epub 2007 Apr 25.

Bragadeesh T, Sari I, Pascotto M, Micari A, Kaul S, Lindner JR. Detection of peripheral vascular stenosis by assessing skeletal muscle flow reserve. J Am Coll Cardiol. 2005 Mar 1;45(5):780-5.

Lindner JR, Womack L, Barrett EJ, Weltman J, Price W, Harthun NL, Kaul S, Patrie JT. Limb stress-rest perfusion imaging with contrast ultrasound for the assessment of peripheral arterial disease severity. JACC Cardiovasc Imaging. 2008 May;1(3):343-50. doi: 10.1016/j.jcmg.2008.04.001.

Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001 Jul 31;104(5):511-4.

Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. Erratum in: J Am Coll Cardiol 2002 Mar 20;39(6):1082.

Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42.

Womack L, Peters D, Barrett EJ, Kaul S, Price W, Lindner JR. Abnormal skeletal muscle capillary recruitment during exercise in patients with type 2 diabetes mellitus and microvascular complications. J Am Coll Cardiol. 2009 Jun 9;53(23):2175-83. doi: 10.1016/j.jacc.2009.02.042.

Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, Seals DR. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H425-32. doi: 10.1152/ajpheart.00689.2008. Epub 2009 May 22.

Gavin KM, Seals DR, Silver AE, Moreau KL. Vascular endothelial estrogen receptor alpha is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women. J Clin Endocrinol Metab. 2009 Sep;94(9):3513-20. doi: 10.1210/jc.2009-0278. Epub 2009 Jun 9.

Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, DuBois NB, Ashton AW, Latif F, Jorde UP, Ware JA, LeJemtel TH. Endothelial cell activation in patients with decompensated heart failure. Circulation. 2005 Jan 4;111(1):58-62. Epub 2004 Dec 20.

Pierce GL, Lesniewski LA, Lawson BR, Beske SD, Seals DR. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation. 2009 Mar 10;119(9):1284-92. doi: 10.1161/CIRCULATIONAHA.108.804294. Epub 2009 Feb 23.

Starting date: August 2010
Last updated: December 2, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017